Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: DDIT4

Summary for DDIT4

Gene information	Gene symbol	DDIT4
	Ensembl ID	ENSG00000168209
	Entrez ID	54541
	Gene name	DNA damage inducible transcript 4
	Synonyms	Dig2\|FLJ20500\|REDD-1\|REDD1\|RTP801
	Gene type	protein_coding
	UniProtAcc	Q9NX09

Top

Dataset with differentially expressed gene: DDIT4

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	0.914121	1.90e-10
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	1.12479	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	-0.484288	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.371845	1.29e-06
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.537193	9.23e-39
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	0.943517	1.87e-15
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.377996	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	0.316113	2.62e-11
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Mono/Macro	-1.61251	7.30e-05
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.1581	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.486726	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.653639	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.639478	5.87e-24
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.383967	1.32e-13
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	NK cells	0.288452	2.88e-36
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-1.03826	2.00e-21
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.478136	2.64e-02
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	-0.850982	2.15e-05
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	B cells	-0.605649	3.96e-03
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.252523	2.63e-03
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	0.280445	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	cDCs	0.31132	2.74e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	1.5979	9.68e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mast cells	1.58753	2.75e-04
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	NK cells	0.912314	6.17e-05
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.602391	3.57e-34
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.563572	3.24e-10
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.721505	1.46e-08
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.831632	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.85706	2.08e-13
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.443377	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-0.519444	7.54e-35
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	-0.369206	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.364402	7.23e-04
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.948678	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.334586	4.43e-07
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.476735	1.14e-31
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	2.15675	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.430319	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.532558	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.551164	2.57e-16
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.808043	2.51e-21
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.460504	1.04e-09
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.545203	0.00e+00
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	0.34178	1.79e-02
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	0.342066	5.50e-14
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	0.312745	4.95e-04
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.478714	4.45e-37
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.31641	2.43e-12
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.260437	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-1.05955	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.74157	0.00e+00

Top

Expression of DDIT4 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to DDIT4

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating DDIT4

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
DDIT4	hsa-miR-6513-3p	99.5893	NM_019058
DDIT4	hsa-miR-5688	99.354	NM_019058
DDIT4	hsa-miR-495-3p	99.2867	NM_019058
DDIT4	hsa-miR-22-3p	96.0818	NM_019058
DDIT4	hsa-miR-548v	91.5072	NM_019058
DDIT4	hsa-miR-545-5p	91.4248	NM_019058
DDIT4	hsa-miR-30b-5p	89.1892	NM_019058
DDIT4	hsa-miR-30d-5p	89.1892	NM_019058
DDIT4	hsa-miR-30a-5p	89.1892	NM_019058
DDIT4	hsa-miR-30e-5p	89.1892	NM_019058
DDIT4	hsa-miR-30c-5p	89.1892	NM_019058
DDIT4	hsa-miR-6516-3p	88.8383	NM_019058
DDIT4	hsa-miR-548ay-5p	86.2273	NM_019058
DDIT4	hsa-miR-548ak	86.2273	NM_019058
DDIT4	hsa-miR-559	86.2273	NM_019058
DDIT4	hsa-miR-548c-5p	86.2273	NM_019058
DDIT4	hsa-miR-548au-5p	86.2273	NM_019058
DDIT4	hsa-miR-548o-5p	86.2273	NM_019058
DDIT4	hsa-miR-548a-5p	86.2273	NM_019058
DDIT4	hsa-miR-548b-5p	86.2273	NM_019058
DDIT4	hsa-miR-548am-5p	86.2273	NM_019058
DDIT4	hsa-miR-548ab	86.2273	NM_019058
DDIT4	hsa-miR-548ae-5p	86.2273	NM_019058
DDIT4	hsa-miR-548d-5p	86.2273	NM_019058
DDIT4	hsa-miR-548bb-5p	86.2273	NM_019058
DDIT4	hsa-miR-548ad-5p	86.2273	NM_019058
DDIT4	hsa-miR-548y	86.2273	NM_019058
DDIT4	hsa-miR-548h-5p	86.2273	NM_019058
DDIT4	hsa-miR-548ap-5p	86.2273	NM_019058
DDIT4	hsa-miR-548j-5p	86.2273	NM_019058
DDIT4	hsa-miR-548ar-5p	86.2273	NM_019058
DDIT4	hsa-miR-548as-5p	86.2273	NM_019058
DDIT4	hsa-miR-548i	86.2273	NM_019058
DDIT4	hsa-miR-548aq-5p	86.2273	NM_019058
DDIT4	hsa-miR-548w	86.2273	NM_019058
DDIT4	hsa-miR-221-3p	86.2208	NM_019058
DDIT4	hsa-miR-187-5p	86.2208	NM_019058
DDIT4	hsa-miR-222-3p	86.2208	NM_019058
DDIT4	hsa-miR-6882-3p	84.8434	NM_019058
DDIT4	hsa-miR-153-3p	84.5447	NM_019058
DDIT4	hsa-miR-7-5p	84.5157	NM_019058
DDIT4	hsa-miR-5194	84.3428	NM_019058
DDIT4	hsa-miR-4262	83.947	NM_019058
DDIT4	hsa-miR-223-3p	83.6626	NM_019058
DDIT4	hsa-miR-4277	83.22	NM_019058
DDIT4	hsa-miR-222-5p	80.1763	NM_019058

Page: 1

Top

Motifs and transcription factors (TFs) regulating DDIT4

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
DDIT4	swissregulon__hs__ETV6	ETV6 (directAnnotation).
DDIT4	transfac_pro__M05298	OVOL3 (directAnnotation).
DDIT4	jaspar__MA1493.1	HES6 (directAnnotation).
DDIT4	taipale_tf_pairs__ERF_HOXA3_RSCGGAWNNNNNNNYMATTA_CAP_repr	ERF; HOXA3 (directAnnotation).
DDIT4	taipale_tf_pairs__ATF4_TEF_RNMTGATGCAATN_CAP	ATF4; TEF (directAnnotation).
DDIT4	taipale_tf_pairs__ATF4_CEBPD_NGATGATGCAATNN_CAP	ATF4; CEBPD (directAnnotation).
DDIT4	metacluster_156.2	ATF3; ATF4; ATF4; ATF4; ATF4; ATF4; ATF4; CEBPG; CEBPG; DDIT3; MYC (directAnnotation). ATF4; ATF4; ATF4; CEBPG; DDIT3 (inferredBy_Orthology).
DDIT4	metacluster_98.1	ZNF524 (directAnnotation).
DDIT4	taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2	ELK1; GCM1 (directAnnotation).
DDIT4	jaspar__MA1125.1	ZNF384 (directAnnotation).
DDIT4	transfac_pro__M01252	E2F6 (directAnnotation).
DDIT4	kznf__ZNF613_Imbeault2017_RP_RCADE	ZNF613 (directAnnotation).
DDIT4	metacluster_130.3	ZNF492; ZNF492 (directAnnotation). OVOL2; OVOL3; PEG3; PLAG1; PLAGL1; PLAGL2; REST; SCAND1; ZKSCAN2; ZNF131; ZNF174; ZNF18; ZNF202; ZNF274; ZNF444; ZNF446; ZNF496; ZNF518A; ZNF518B; ZNF576; ZNF641; ZNF770; ZSCAN1; ZSCAN18; ZSCAN29; ZSCAN32; ZSCAN5A; ZSCAN5B; ZSCAN5C (inferredBy_Orthology).
DDIT4	kznf__ZNF182_Imbeault2017_OM_RCADE	ZNF182 (directAnnotation).
DDIT4	kznf__CTCF_Rhee2011.2_ChIP-exo	CTCF (directAnnotation).
DDIT4	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
DDIT4	metacluster_130.2	ZNF182; ZNF22; ZNF225; ZNF225; ZNF285; ZNF362; ZNF362; ZNF384; ZNF487; ZNF512; ZNF570; ZNF613 (directAnnotation). ZNF384 (inferredBy_Orthology).
DDIT4	tfdimers__MD00421	ELF3; POU5F1 (directAnnotation).
DDIT4	transfac_pro__M07431	SOX11 (directAnnotation).
DDIT4	hocomoco__FOXP1_HUMAN.H11MO.0.A	FOXP1 (directAnnotation).
DDIT4	metacluster_188.6	DLX6; FOXA1; FOXA1; FOXA2; FOXA2; FOXA3; FOXA3; FOXC1; FOXC1; FOXC2; FOXC2; FOXC2; FOXC2; FOXD2; FOXD3; FOXD3; FOXE1; FOXE1; FOXE1; FOXJ2; FOXJ2; FOXK1; FOXL1; FOXL1; FOXM1; FOXP1; FOXP1; HMG20B; IKZF5; SKI (directAnnotation). FOXD2; FOXF1; FOXJ3; FOXK1; FOXL1; FOXL1 (inferredBy_Orthology).
DDIT4	flyfactorsurvey__fd64A_SANGER_5_FBgn0004895	FOXL1 (inferredBy_Orthology).
DDIT4	transfac_pro__M01216	FOXG1; FOXO1 (directAnnotation).
DDIT4	metacluster_77.10	SRY (inferredBy_Orthology).
DDIT4	tfdimers__MD00204	GABPA; NKX2-1 (directAnnotation).
DDIT4	metacluster_130.15	ARID5B; ARID5B; BPTF (directAnnotation).
DDIT4	transfac_public__M00415	ZEB1 (directAnnotation).
DDIT4	transfac_pro__M08883	FOXM1 (directAnnotation).
DDIT4	transfac_pro__M06939	ZBTB11 (directAnnotation).
DDIT4	metacluster_188.5	FOXA1; FOXA2; FOXA2; FOXA3; FOXD3; FOXD3; FOXF1; FOXF1; FOXF1; FOXF1; FOXF2; FOXG1; FOXH1; FOXI1; FOXI1; FOXI1; FOXJ1; FOXJ2; FOXL1; FOXO1; FOXO3; FOXO4; FOXO4; FOXQ1 (directAnnotation). FOXK1; FOXL2 (inferredBy_Orthology).
DDIT4	transfac_pro__M03888	SOX6 (directAnnotation).
DDIT4	transfac_pro__M08882	FOXC2 (directAnnotation).
DDIT4	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
DDIT4	transfac_pro__M04860	RXRA (directAnnotation).
DDIT4	metacluster_32.45	HDAC2 (directAnnotation).
DDIT4	metacluster_127.3	FOXO1; FOXO3; FOXO4 (directAnnotation).
DDIT4	transfac_pro__M07255	FOXM1 (directAnnotation).
DDIT4	metacluster_190.7	ILF2; NFATC1; NFATC1; NFATC1; NFATC1; NFATC2; NFATC2; NFATC2; NFATC3; NFATC3; NFATC3; NFATC3; NFATC4; NFATC4; NFATC4 (directAnnotation).
DDIT4	hdpi__RAN	RAN (directAnnotation).
DDIT4	metacluster_32.32	PRDM6 (directAnnotation).
DDIT4	swissregulon__hs__NFATC2	NFATC2 (directAnnotation).
DDIT4	transfac_pro__M07608	ILF2; NFAT5; NFATC1; NFATC2; NFATC4 (directAnnotation).
DDIT4	transfac_pro__M01886	NFATC3 (directAnnotation).
DDIT4	transfac_pro__M07607	NFATC3 (directAnnotation).
DDIT4	transfac_pro__M05731	ZNF660 (directAnnotation).
DDIT4	c2h2_zfs__M0369	BCL6B (inferredBy_Orthology).
DDIT4	hocomoco__PRDM6_HUMAN.H11MO.0.C	PRDM6 (directAnnotation).
DDIT4	cisbp__M05891	SOX10 (directAnnotation).
DDIT4	transfac_pro__M06366	ZNF530 (directAnnotation).
DDIT4	transfac_pro__M02015	FOXA3 (directAnnotation).

Page: 1 2 3 4 5 6

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."